These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 19785380)

  • 1. [To treat or not to treat with statins patients with chronic heart failure?].
    Hradec J
    Vnitr Lek; 2009 Sep; 55(9):802-7. PubMed ID: 19785380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure).
    Cleland JG; McMurray JJ; Kjekshus J; Cornel JH; Dunselman P; Fonseca C; Hjalmarson A; Korewicki J; Lindberg M; Ranjith N; van Veldhuisen DJ; Waagstein F; Wedel H; Wikstrand J;
    J Am Coll Cardiol; 2009 Nov; 54(20):1850-9. PubMed ID: 19892235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosuvastatin in older patients with systolic heart failure.
    Kjekshus J; Apetrei E; Barrios V; Böhm M; Cleland JG; Cornel JH; Dunselman P; Fonseca C; Goudev A; Grande P; Gullestad L; Hjalmarson A; Hradec J; Jánosi A; Kamenský G; Komajda M; Korewicki J; Kuusi T; Mach F; Mareev V; McMurray JJ; Ranjith N; Schaufelberger M; Vanhaecke J; van Veldhuisen DJ; Waagstein F; Wedel H; Wikstrand J;
    N Engl J Med; 2007 Nov; 357(22):2248-61. PubMed ID: 17984166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [No reason to start treatment with statins in patients with moderate to severe heart failure].
    Stalenhoef AF
    Ned Tijdschr Geneeskd; 2008 Mar; 152(9):486-8. PubMed ID: 18389878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure.
    Krum H; Ashton E; Reid C; Kalff V; Rogers J; Amarena J; Singh B; Tonkin A
    J Card Fail; 2007 Feb; 13(1):1-7. PubMed ID: 17338996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA.
    Ueland T; Dahl CP; Kjekshus J; Hulthe J; Böhm M; Mach F; Goudev A; Lindberg M; Wikstrand J; Aukrust P; Gullestad L
    Circ Heart Fail; 2011 Mar; 4(2):145-52. PubMed ID: 21216833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
    Gullestad L; Ueland T; Kjekshus J; Nymo SH; Hulthe J; Muntendam P; Adourian A; Böhm M; van Veldhuisen DJ; Komajda M; Cleland JG; Wikstrand J; McMurray JJ; Aukrust P;
    Eur Heart J; 2012 Sep; 33(18):2290-6. PubMed ID: 22513778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of statins in the treatment of heart failure].
    Eren M
    Turk Kardiyol Dern Ars; 2009 Oct; 37(7):501-11. PubMed ID: 20098048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials.
    Latini R; Gullestad L; Masson S; Nymo SH; Ueland T; Cuccovillo I; Vårdal M; Bottazzi B; Mantovani A; Lucci D; Masuda N; Sudo Y; Wikstrand J; Tognoni G; Aukrust P; Tavazzi L;
    Eur J Heart Fail; 2012 Sep; 14(9):992-9. PubMed ID: 22740508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.
    McMurray JJ; Kjekshus J; Gullestad L; Dunselman P; Hjalmarson A; Wedel H; Lindberg M; Waagstein F; Grande P; Hradec J; Kamenský G; Korewicki J; Kuusi T; Mach F; Ranjith N; Wikstrand J;
    Circulation; 2009 Dec; 120(22):2188-96. PubMed ID: 19917888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial.
    Marchioli R; Levantesi G; Silletta MG; Barlera S; Bernardinangeli M; Carbonieri E; Cosmi F; Franzosi MG; Latini R; Lucci D; Maggioni AP; Moretti L; Nicolosi GL; Porcu M; Rossi MG; Tognoni G; Tavazzi L;
    Expert Rev Cardiovasc Ther; 2009 Jul; 7(7):735-48. PubMed ID: 19589110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
    Askevold ET; Nymo S; Ueland T; Gravning J; Wergeland R; Kjekshus J; Yndestad A; Cleland JG; McMurray JJ; Aukrust P; Gullestad L
    Circ Heart Fail; 2013 Jan; 6(1):91-8. PubMed ID: 23230311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study.
    Michos ED; Blumenthal RS
    J Am Coll Cardiol; 2009 Mar; 53(11):931-5. PubMed ID: 19281922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial.
    Maggioni AP; Fabbri G; Lucci D; Marchioli R; Franzosi MG; Latini R; Nicolosi GL; Porcu M; Cosmi F; Stefanelli S; Tognoni G; Tavazzi L;
    Eur Heart J; 2009 Oct; 30(19):2327-36. PubMed ID: 19717850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ongoing trials and future prospects].
    Baldasseroni S; Fabbri G; Maggioni AP
    Ital Heart J; 2003 Dec; 4 Suppl 7():58S-64S. PubMed ID: 14983747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
    Stewart RA
    Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.
    Tavazzi L; Maggioni AP; Marchioli R; Barlera S; Franzosi MG; Latini R; Lucci D; Nicolosi GL; Porcu M; Tognoni G;
    Lancet; 2008 Oct; 372(9645):1231-9. PubMed ID: 18757089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
    Fonseca FA; Izar MC
    Expert Rev Cardiovasc Ther; 2009 Sep; 7(9):1041-56. PubMed ID: 19764857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).
    O'Keefe JH; Carter MD; Lavie CJ; Bell DS
    Postgrad Med; 2009 May; 121(3):113-8. PubMed ID: 19491548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program.
    Shepherd J; Vidt DG; Miller E; Harris S; Blasetto J
    Cardiology; 2007; 107(4):433-43. PubMed ID: 17363845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.